
Home / News
-
-
-
Fapon and KIVDA Sign Strategic Agreement to Deepen China-Korea IVD Collaboration On 23 May, Fapon Biotech signed a strategic cooperation agreement with the Korea In Vitro Diagnostics Associ..2025-05-27View More
-
-
-
-
Chinese President Xi Jinping arrived in Hanoi on Monday to pay a state visit to Vietnam.2025-04-15View More
-
-
-
-
AdvaMed and nine other healthcare organizations have continued to pressure the White House to exempt medical devices and critical supplies from the Trump administration¡¯s ongoing tariff saga.2025-04-09View More
-
-
-
-
At the 7th China International Import Expo (CIIE), themed "New Era, Shared Future", representatives from 152 countries, regions, and organizations gathered for national and corporate exhibitions. On 8 November, Switze..2024-11-15View More
-
-
-
-
As of August 31, 2025, China has 83 publicly listed companies related to in vitro diagnostics (IVD), including 62 whose core business is IVD and 21 with IVD-related operations. Among the 62 core IVD companies, 59 have..2025-09-25View More
-
-
-
-
Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad¡¯s advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS¡¯ broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment.2025-09-25View More
-
-
-
-
The U.S. Commerce Department said on Wednesday it has opened new national security investigations into the import of personal protective equipment, medical items, robotics and industrial machinery.2025-09-25View More
-
-
-
-
Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. Through a multi-year agreement, Quest¡¯s provider clients that order lab testing from Quest will be able to directly order Shield through their existing Quest account and electronic health record (EHR). Quest provided healthcare connectivity solutions to approximately 650,000 clinician and hospital accounts last year. Quest¡¯s provider clients will also be able to refer patients to Quest¡¯s 2,000 patient service centers and 6,000 in-office phlebotomists for blood draws in the United States. In addition, Quest¡¯s national commercial sales team will proactively educate primary care physicians and obstetricians and gynecologists about the test, accelerating awareness among Quest¡¯s ordering providers. Shield is expected to be available for physician order through Quest in the first quarter of 2026.2025-09-25View More
-
-
-
-
Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech Limited (NASDAQ: BNR, ¡°Burning Rock¡±) today announced that the OncoGuide™ OncoScreen™ Plus CDx System based on OncoScreen™ Plus to be used as a companion diagnostic for AstraZeneca¡¯s capivasertib has received Manufacturing and Marketing Approval from Japan¡¯s Ministry of Health, Labour and Welfare (MHLW).2025-09-25View More
-
-
-
-
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs.2025-09-24View More
-
-
-
-
The US Food and Drug Administration (FDA) issued finalized guidance on Monday outlining the criteria for authorizing emergency use of unapproved in vitro diagnostic tests (IVDs) during future public health emergencies.2025-09-24View More
-
-
-
-
Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, and Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, today announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions. The collaboration will leverage Lunit's AI technology and Agilent's expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development.2025-09-23View More
-
-
-
-
Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity¡¯s established Pin-pointTM base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit.2025-09-23View More
-
-
-
-
2.2 Blood Coagulation Reagents Thrombotic diseases, in particular cardiovascular and cerebrovascular thrombotic diseases, have become the top cause of death in the population of China, and their incidence has in..2025-09-22View More
-
-
-
-
Diasorin (FTSE MIB: DIA) today announces the launch of the new LIAISON® TSH-R Ab assay, available in all countries recognizing the CE Mark. This assay is specifically developed to aid in the diagnosis and monitoring of patients with suspected Graves¡¯ Disease, an autoimmune disorder characterized by autoantibodies, TSH-Receptor antibodies (TSH-R Ab), that can stimulate thyroid receptors, leading to increased production and release of hormones by the gland.2025-09-22View More
-
-
-
-
The Food and Drug Administration has rescinded its final rule on laboratory developed tests, formally ending a decades-long effort to expand oversight of the lab industry.2025-09-22View More
-
-
-
-
Qiagen is partnering with Oxford Gene Technology, a Sysmex subsidiary, to comarket and distribute its Qiagen Clinical Insight (QCI) Interpret software with OGT's SureSeq NGS panels, the firms announced Thursday. Financial terms were not disclosed.2025-09-19View More
-
-
-
-
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has categorized its Ionify® 25-Hydroxy Vitamin D total assay as ¡°Moderate Complexity¡± under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). This represents the first time a mass spectrometry-based test has achieved this designation, opening access to a broader range of clinical laboratories.2025-09-19View More
-
-
-
-
Original from: PR Newswire The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of ..2025-09-18View More
-
-
-
-
Biocartis Group of Companies (¡°Biocartis¡±), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ CDx MSI Test developed in partnership with Bristol Myers Squibb, has received the first-ever Premarket Approval (PMA) from the FDA for a cartridge-based, fully automated, ¡°sample-to-result¡± companion diagnostic test.2025-09-18View More
-
- CAIVD WeChat
Subscription Account
- CAIVD WeChat
Channels
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.